Compounds > cysmethynil
Page last updated: 2024-10-14

cysmethynil

Description

cysmethynil: an Icmt inhibitor with antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6918831
CHEMBL ID240860
SCHEMBL ID2013327
MeSH IDM0523836

Synonyms (21)

Synonym
a-119044
9j20
cysmethynil
CHEMBL240860 ,
2-[5-(3-methylphenyl)-1-octylindol-3-yl]acetamide
2-(1-octyl-5-m-tolyl-1h-indol-3-yl)acetamide
bdbm50327696
851636-83-4
1h-indole-3-acetamide, 5-(3-methylphenyl)-1-octyl-
SCHEMBL2013327
DTXSID90426093
AKOS032947852
BCP21581
Q5201174
2-[5-(3-methylphenyl)-1-octyl-1h-indol-3-yl] acetamide
HMS3740K09
2-(1-octyl-5-(m-tolyl)-1h-indol-3-yl)acetamide
icmt inhibitor
5-(3-methylphenyl)-1-octyl-1h-indole-3-acetamide
unii-r5mt8hfq9e
r5mt8hfq9e ,

Treatment

ExcerptReference
"Cysmethynil-treated cells displayed reduced mammalian target of rapamycin (mTOR) signaling, providing a potential mechanism for the excessive autophagy as well as G(1) cell cycle arrest observed."( A small molecule inhibitor of isoprenylcysteine carboxymethyltransferase induces autophagic cell death in PC3 prostate cancer cells.
Casey, PJ; Go, M; Lee, HS; Leow, J; Tan, W; Wang, M; Zhou, J, 2008)

Dosage Studied

ExcerptReference
" This sensitive method was used to quantify cysmethynil in plasma of mice after intraperitoneal dosing for preliminary pharmacokinetic studies."( A high-performance liquid chromatography method for the quantification of cysmethynil, an inhibitor of isoprenylcysteine carboxylmethyl transferase, in mouse plasma.
Casey, P; Khoo, YM; Lee, HS; Wang, M; Zhou, J, 2009)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (5)

PathwayProteinsCompounds
Signaling Pathways1269117
MAPK family signaling cascades11519
ERK1/ERK2 pathway9319
RAF/MAP kinase cascade9119
RAS processing1318

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)IC50 (µMol)2.05791.50002.05792.4000AID305651; AID516956; AID607234; AID744451; AID754519
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
C-terminal protein methylationProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
protein targeting to membraneProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
protein modification processProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
S-adenosylhomocysteine metabolic processProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
S-adenosylmethioninamine metabolic processProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
protein C-terminal carboxyl O-methyltransferase activityProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
protein C-terminal S-isoprenylcysteine carboxyl O-methyltransferase activityProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
protein bindingProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
endoplasmic reticulumProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
endoplasmic reticulum membraneProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
membraneProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
endoplasmic reticulumProtein-S-isoprenylcysteine O-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID744445Aqueous solubility of the compound at pH 7.4 after 24 hrs agitation2013European journal of medicinal chemistry, May, Volume: 63Functionalized indoleamines as potent, drug-like inhibitors of isoprenylcysteine carboxyl methyltransferase (Icmt).
AID1562336Induction of apoptosis in human PC3 cells assessed as increase in cleaved PARP expression at 25 uM measured after 24 hrs by Western blot analysis2019Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13
A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia.
AID305651Inhibition of ICMT expressed in Sf9 cells2007Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
Quantitative structure-activity relationship (QSAR) of indoloacetamides as inhibitors of human isoprenylcysteine carboxyl methyltransferase.
AID1562326Inhibition of ICMT in human PC3 cells assessed as induction of mislocalization of endogenous Ras at 5 uM preincubated for 48 hrs followed by compound washout and subsequent compound addition measured after 72 hrs by Hoechst 33258 staining-based confocal m2019Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13
A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia.
AID1562359Induction of apoptosis in human Capan2 cells assessed as increase in sub-G0/G1 population at 50 uM measured after 24 hrs by propidium iodide staining based flow cytometry2019Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13
A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia.
AID744450Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay2013European journal of medicinal chemistry, May, Volume: 63Functionalized indoleamines as potent, drug-like inhibitors of isoprenylcysteine carboxyl methyltransferase (Icmt).
AID744449Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay2013European journal of medicinal chemistry, May, Volume: 63Functionalized indoleamines as potent, drug-like inhibitors of isoprenylcysteine carboxyl methyltransferase (Icmt).
AID744444Permeability of the compound at 5 uM after 16 hrs agitation by PAMPA2013European journal of medicinal chemistry, May, Volume: 63Functionalized indoleamines as potent, drug-like inhibitors of isoprenylcysteine carboxyl methyltransferase (Icmt).
AID1562357Induction of apoptosis in human PANC1 cells assessed as increase in sub-G0/G1 population at 50 uM measured after 24 hrs by propidium iodide staining based flow cytometry2019Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13
A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia.
AID516957Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by colorimetric tetrazolium assay2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Amino derivatives of indole as potent inhibitors of isoprenylcysteine carboxyl methyltransferase.
AID1562341Inhibition of ICMT in human AD293 cells transfected GFP-fused K-Ras4B assessed as induction of K-Ras4B mislocalization at 5 uM by laser scanning confocal microscopic analysis2019Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13
A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia.
AID754519Inhibition of recombinant ICMT (unknown origin) expressed in sf9 cells using biotin S-farnesyl-L-cysteine as substrate2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.
AID1562355Induction of apoptosis in human MIAPaCa2 cells assessed as increase in sub-G0/G1 population at 50 uM measured after 24 hrs by propidium iodide staining based flow cytometry2019Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13
A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia.
AID744451Inhibition of recombinant Icmt (unknown origin) expressed in Sf9 cells assessed as transfer of methyl group from [3H]-S-adenosylmethionine to [3H]-biotin-S-farnesyl-L-cysteine after 30 mins2013European journal of medicinal chemistry, May, Volume: 63Functionalized indoleamines as potent, drug-like inhibitors of isoprenylcysteine carboxyl methyltransferase (Icmt).
AID744441Half life in rat liver microsomes at 3 uM2013European journal of medicinal chemistry, May, Volume: 63Functionalized indoleamines as potent, drug-like inhibitors of isoprenylcysteine carboxyl methyltransferase (Icmt).
AID744446Antiproliferative activity against human IMR90 cells after 72 hrs by MTT assay2013European journal of medicinal chemistry, May, Volume: 63Functionalized indoleamines as potent, drug-like inhibitors of isoprenylcysteine carboxyl methyltransferase (Icmt).
AID1562335Induction of autophagy in human PC3 cells assessed as increase in LC3 expression at 25 uM measured after 24 hrs by Western blot analysis2019Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13
A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia.
AID1562358Induction of apoptosis in human PK9 cells assessed as increase in sub-G0/G1 population at 50 uM measured after 24 hrs by propidium iodide staining based flow cytometry2019Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13
A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia.
AID1562338Inhibition of ICMT in human AD293 cells transfected GFP-fused H-Ras assessed as induction of H-Ras mislocalization at 5 uM by laser scanning confocal microscopic analysis2019Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13
A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia.
AID744442Intrinsic clearance in rat liver microsomes at 3 uM2013European journal of medicinal chemistry, May, Volume: 63Functionalized indoleamines as potent, drug-like inhibitors of isoprenylcysteine carboxyl methyltransferase (Icmt).
AID1562340Inhibition of ICMT in human AD293 cells transfected GFP-fused K-Ras4A assessed as induction of K-Ras4A mislocalization at 5 uM by laser scanning confocal microscopic analysis2019Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13
A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia.
AID1562337Induction of apoptosis in human PC3 cells assessed as increase in caspase 3 activity at 25 uM2019Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13
A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia.
AID1562356Induction of apoptosis in human HUPT4 cells assessed as increase in sub-G0/G1 population at 50 uM measured after 24 hrs by propidium iodide staining based flow cytometry2019Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13
A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia.
AID744448Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay2013European journal of medicinal chemistry, May, Volume: 63Functionalized indoleamines as potent, drug-like inhibitors of isoprenylcysteine carboxyl methyltransferase (Icmt).
AID1562342Effect on GFP-fused Fyn (unknown origin) transfected in human AD293 cells assessed as induction of Fyn mislocalization at 5 uM by laser confocal microscopic analysis2019Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13
A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia.
AID516956Inhibition of recombinant ICMT expressed in Sf9 cells using [3H] AdoMet after 20 mins by scintillation counting2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Amino derivatives of indole as potent inhibitors of isoprenylcysteine carboxyl methyltransferase.
AID1562339Inhibition of ICMT in human AD293 cells transfected GFP-fused N-Ras assessed as induction of N-Ras mislocalization at 5 uM by laser scanning confocal microscopic analysis2019Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13
A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia.
AID607234Inhibition of recombinant ICMT expressed in Sf9 cells using [3H]-AdoMet after 20 mins by scintillation counter2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Discovery and SAR of methylated tetrahydropyranyl derivatives as inhibitors of isoprenylcysteine carboxyl methyltransferase (ICMT).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (22.22)29.6817
2010's13 (72.22)24.3611
2020's1 (5.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		2.0810aromatic ether;
nitrile;
polyether;
tertiary amino compound
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.2110nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
santowhite powder
4,4'-butylidenebis(6-tert-butyl-m-cresol): putatively both an androgen and estrogen antagonist; structure in first source		3.1810
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		2.110azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
triphenyltetrazolium
triphenyltetrazolium: RN given refers to parent cpd. 2,3,5-triphenyltetrazolium : An organic cation that is tetrazole carrying three phenyl substituents at positions 2, 3 and 5.		3.1810organic cation
carboxyamido-triazole
carboxyamido-triazole: structure given in first source; coccidiostat; U.S. patent No. 4,590,201		3.1810
imatinib mesylate
imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.		2.1310methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
gefitinib
[no description available]		2.110aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
lonafarnib
lonafarnib: inhibitor of farnesyl protein transferase. lonafarnib : A 4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide that has R configuration. It is used as oral farnesyltransferase inhibitor.		2.21104-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamideantineoplastic agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
lanperisone
lanperisone : A 2-methyl-3-(pyrrolidin-1-yl)-1-[4-(trifluoromethyl)phenyl]propan-1-one in which the methyl group at position 2 adopts R-configuration. It is a muscle relaxant and induces ferroptosis in cancer cells.		3.18102-methyl-3-(pyrrolidin-1-yl)-1-[4-(trifluoromethyl)phenyl]propan-1-oneantineoplastic agent;
calcium channel blocker;
ferroptosis inducer;
muscle relaxant;
voltage-gated sodium channel blocker
bms 214662
7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine: a farnesyltransferase inhibitor; structure in first source. BMS-214662 : A member of the class of benzodiazepines that is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine substituted by (1H-imidazol-5-yl)methyl, benzyl, (thiophen-2-yl)sulfonyl, and cyano groups at positions 1, 3R, 4 and 7, respectively. It is a potent inhibitor of farnesyltransferase (IC50 = 1.35nM) which was under clinical development for the treatment of solid tumors.		3.1810benzenes;
benzodiazepine;
imidazoles;
nitrile;
sulfonamide;
thiophenes		antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
oncrasin-1
oncrasin-1: an antineoplastic agent; structure in first source. oncrasin-1 : A member of the class of indoles that is 1H-indole substituted by 4-chlorobenzyl and formyl groups at positions 1 and 3, respectively. It is an anti-cancer agent that is active against lung cancer cells with K-Ras mutations.		3.1810arenecarbaldehyde;
indoles;
monochlorobenzenes		antineoplastic agent;
apoptosis inducer
bi 2536
[no description available]		3.1810
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Myelogenous Leukemia
[description not available]		02.2110
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		02.2110
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		02.2510
Hepatitis
INFLAMMATION of the LIVER.		02.2510
Benign Neoplasms
[description not available]		03.4120
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.4120
Epithelial Ovarian Cancer
[description not available]		02.1710
Epithelial Neoplasms
[description not available]		02.1710
Cancer of Ovary
[description not available]		02.1710
Carcinoma, Ovarian Epithelial
A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.		02.1710
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.1710
Nasopharyngeal Carcinoma
A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.		02.2110
Cancer of Nasopharynx
[description not available]		02.2110
Nasopharyngeal Neoplasms
Tumors or cancer of the NASOPHARYNX.		02.2110
Cancer of Liver
[description not available]		02.110
Liver Neoplasms
Tumors or cancer of the LIVER.		02.110
Carcinogenesis
The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.		02.1110
Granulocytic Leukemia, Chronic
[description not available]		02.1310
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.		02.1310
Lung Adenocarcinoma
[description not available]		02.1310
Adenocarcinoma, Basal Cell
[description not available]		02.1310
Cancer of Lung
[description not available]		02.1310
Angiogenesis, Pathologic
[description not available]		02.1310
Adenocarcinoma of Lung
A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.		02.1310
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.1310
Lung Neoplasms
Tumors or cancer of the LUNG.		02.1310
Pleural Effusion, Malignant
Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.		02.1310
Breast Cancer
[description not available]		02.0510
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0510
Cancer of Prostate
[description not available]		02.0410
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.0410